In fact, EGFR mutations were the most frequently identified actionable genetic aberrations using the NCC OncoPanel, even in patients with NSCLC, in whom no EGFR mutations or ALK fusions were detected using single companion diagnostics.35 This evidence concerns the gene ALK and non-small cell lung carcinoma.